Novartis, Genentech Get Expanded FDA OK of Xolair for Nasal Polyps
By Colin Kellaher
Novartis AG and Roche Holding AG's Genentech unit on Tuesday
said the Food and Drug Administration approved the expanded use of
Xolair for the add-on maintenance treatment of nasal polyps in
adults with inadequate response to intranasal corticosteroids.
The companies said the approval makes Xolair the first biologic
for the treatment of nasal polyps that targets and blocks
immunoglobulin E, a key driver of inflammation.
Nasal polyps, which can lead to nasal congestion and a loss of
smell, frequently occur with other respiratory conditions, such as
allergies and asthma.
Xolair was already approved in the U.S. to treat moderate to
severe persistent allergic asthma and chronic idiopathic urticaria.
Novartis and Genentech work together to develop and co-promote
Xolair in the U.S.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
December 01, 2020 12:11 ET (17:11 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.